UK 356618

UK 356618

CAT N°: 32859
Price:

From 182.00 154.70

UK 356618 is an inhibitor of matrix metalloproteinase-3 (MMP-3; IC50 = 5.9 nM).{58238} It is selective for MMP-3 over MMP-1, -2, -9, -13, and -14 (IC50s = 51, 1.79, 0.84, 0.073, and 1.9 µM, respectively). UK 356618 (73 nM) inhibits IL-6-induced migration of NCI H446 small cell lung cancer (SCLC) cells in vitro.{58239} It reduces hyperglycemia-exacerbated increases in brain edema and hemorrhagic transformation in the cortex and striatum in a rat model of ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO) when administered intravenously at a dose of 15 mg/kg.{58240}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (2R)-N1-[(1S)-2,2-dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1?-biphenyl]-4-yl)propyl]-butanediamide
  • Correlated keywords
    • MMP3 UK356618 metalloproteinase3 MMP1 MMP2 MMP9 MMP13 MMP14 IL6 NClH446 hyperglycemiaexacerbated
  • Product Overview:
    UK 356618 is an inhibitor of matrix metalloproteinase-3 (MMP-3; IC50 = 5.9 nM).{58238} It is selective for MMP-3 over MMP-1, -2, -9, -13, and -14 (IC50s = 51, 1.79, 0.84, 0.073, and 1.9 µM, respectively). UK 356618 (73 nM) inhibits IL-6-induced migration of NCI H446 small cell lung cancer (SCLC) cells in vitro.{58239} It reduces hyperglycemia-exacerbated increases in brain edema and hemorrhagic transformation in the cortex and striatum in a rat model of ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO) when administered intravenously at a dose of 15 mg/kg.{58240}

We also advise you